Gilligan A K, Markus R, Read S, Srikanth V, Hirano T, Fitt G, Arends M, Chambers B R, Davis S M, Donnan G A
National Stroke Research Institute and University of Melbourne Department of Medicine, Austin and Repatriation Medical Centre, Heidelberg West, Victoria, Australia.
Stroke. 2002 Sep;33(9):2236-42. doi: 10.1161/01.str.0000027859.59415.66.
Intracerebral hemorrhage is the most serious complication of thrombolytic therapy for stroke. We explored factors associated with this complication in the Australian Streptokinase Trial.
The initial CT scans (< or =4 hours after stroke) of 270 patients were reviewed retrospectively by an expert panel for early signs of ischemia and classified into the following 3 categories: no signs or < or =1/3 or >1/3 of the vascular territory. Hemorrhage on late CT scans was categorized as major or minor on the basis of location and mass effect. Stepwise, backward elimination, multivariate logistic regression analysis was used to identify risk factors for each hemorrhage category.
Major hemorrhage occurred in 21% of streptokinase (SK) and 4% of placebo patients. Predictors of major hemorrhage were SK treatment (odds ratio [OR], 6.40; 95% CI, 2.50 to 16.36) and elevated systolic blood pressure before therapy (OR, 1.03; 95% CI, 1.01 to 1.05). Baseline systolic blood pressure >165 mm Hg in SK-treated patients resulted in a >25% risk of major secondary hemorrhage. Early ischemic CT changes, either < or =1/3 or >1/3, were not associated with major hemorrhage (OR, 1.58; 95% CI, 0.65 to 3.83; and OR, 1.11; 95% CI, 0.45 to 2.76, respectively). Minor hemorrhage occurred in 30% of the SK and 26% of the placebo group. Predictors of minor hemorrhage were male sex, severe stroke, early CT changes, and SK treatment. Ninety-one percent of patients with major hemorrhage deteriorated clinically compared with 23% with minor hemorrhage.
SK increased the risk of both minor and major hemorrhage. Major hemorrhage was also more likely in patients with elevated baseline systolic blood pressure. However, early CT changes did not predict major hemorrhage. Results from this study highlight the importance of baseline systolic blood pressure as a potential cause of hemorrhage in patients undergoing thrombolysis.
脑出血是中风溶栓治疗最严重的并发症。我们在澳大利亚链激酶试验中探究了与该并发症相关的因素。
由一个专家小组对270例患者的初始CT扫描(中风后≤4小时)进行回顾性分析,以寻找早期缺血迹象,并将其分为以下3类:无迹象、血管区域≤1/3或>1/3。后期CT扫描上的出血根据位置和占位效应分为严重或轻微出血。采用逐步向后排除的多变量逻辑回归分析来确定每种出血类型的危险因素。
链激酶(SK)治疗组21%的患者和安慰剂组4%的患者发生严重出血。严重出血的预测因素为SK治疗(比值比[OR],6.40;95%置信区间[CI],2.50至16.36)和治疗前收缩压升高(OR,1.03;95%CI,1.01至1.05)。SK治疗的患者基线收缩压>165mmHg导致严重继发性出血的风险>25%。早期缺血性CT改变,无论是≤1/3还是>1/3,均与严重出血无关(OR分别为1.58;95%CI,0.65至3.83;以及OR,1.11;95%CI,0.45至2.76)。轻微出血发生在SK治疗组30%的患者和安慰剂组26%的患者中。轻微出血的预测因素为男性、严重中风、早期CT改变和SK治疗。91%发生严重出血的患者临床症状恶化,而发生轻微出血的患者中这一比例为23%。
SK增加了轻微和严重出血的风险。基线收缩压升高的患者发生严重出血的可能性也更高。然而,早期CT改变并不能预测严重出血。本研究结果突出了基线收缩压作为溶栓治疗患者出血潜在原因的重要性。